After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have “brain fog,” or forgetfulness and difficulty concentrating. A ...

A research team from University Hospital Cologne and the University of Cologne’s Faculty of Medicine, led by Professor Dr Dr Roland Ullrich, Senior Physician at the Clinic I of Internal Medicine, has ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

Researchers have found that CAR T-cell therapy can help aging intestines heal by targeting senescent cells. In mice, it ...

Researchers have discovered a novel way to help ageing intestines repair themselves using CAR T-cell therapy, a breakthrough that could one day improve gut health in older adults and cancer patients.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's unique ...